See more : Denny’s Corporation (DENN) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectis S.A. (CLLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectis S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Stratabound Minerals Corp. (SB.V) Income Statement Analysis – Financial Results
- Raminfo Limited (RAMINFO.BO) Income Statement Analysis – Financial Results
- Oncopeptides AB (publ) (ONPPF) Income Statement Analysis – Financial Results
- PNGS GARGI FASHION JEWELLERY L (GARGI.BO) Income Statement Analysis – Financial Results
- MedX Health Corp (MDXHF) Income Statement Analysis – Financial Results
Cellectis S.A. (CLLS)
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 755.00K | 19.17M | 73.95M | 73.95M | 15.19M | 12.73M | 25.19M | 42.58M | 55.04M | 26.30M | 22.82M | 27.81M | 20.73M | 20.98M | 17.32M | 14.77M | 4.10M |
| Cost of Revenue | 737.00K | 1.77M | 36.28M | 36.28M | 11.39M | 2.74M | 2.62M | 1.69M | 2.71M | 3.69M | 847.86K | 2.03M | 3.26M | 1.92M | 2.33M | 1.54M | 1.48M |
| Gross Profit | 18.00K | 17.40M | 37.67M | 37.67M | 3.80M | 9.99M | 22.57M | 40.90M | 52.34M | 22.61M | 21.97M | 25.78M | 17.47M | 19.06M | 14.99M | 13.23M | 2.62M |
| Gross Profit Ratio | 2.38% | 90.76% | 50.95% | 50.95% | 25.00% | 78.49% | 89.60% | 96.04% | 95.08% | 85.97% | 96.28% | 92.70% | 84.27% | 90.84% | 86.57% | 89.56% | 63.99% |
| Research & Development | 87.65M | 97.50M | 86.95M | 86.95M | 92.04M | 76.57M | 79.23M | 74.56M | 57.30M | 17.52M | 34.44M | 25.10M | 15.95M | 16.37M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.81M | 17.49M | 37.87M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 0.00 | 0.00 | 0.00 | 7.97M | 5.70M | 4.28M |
| Selling & Marketing | 0.00 | 3.11M | 6.33M | 1.66M | 11.43M | 16.69M | 9.14M | 8.41M | 6.67M | 6.57M | 18.14M | 0.00 | 0.00 | 17.90M | 0.00 | 0.00 | 0.00 |
| SG&A | 16.81M | 17.49M | 44.20M | 44.20M | 43.02M | 47.25M | 44.75M | 41.26M | 29.78M | 15.95M | 30.49M | 25.83M | 26.69M | 17.90M | 7.97M | 5.70M | 4.28M |
| Other Expenses | -7.14M | -7.93M | -8.04M | -8.04M | -7.71M | -25.42M | -17.90M | -19.38M | -10.88M | -11.05M | -15.95M | 995.85K | 142.57K | 35.91K | 19.54M | 12.32M | 4.37K |
| Operating Expenses | 97.32M | 107.07M | 123.11M | 123.11M | 127.35M | 115.08M | 115.22M | 104.86M | 82.87M | 28.98M | 67.13M | 51.92M | 42.78M | 34.31M | 27.51M | 18.03M | 10.41M |
| Cost & Expenses | 98.06M | 108.84M | 159.39M | 159.39M | 138.74M | 117.82M | 117.84M | 106.54M | 85.57M | 32.68M | 67.97M | 53.95M | 46.04M | 36.23M | 29.84M | 19.57M | 11.88M |
| Interest Income | 3.61M | 1.12M | 736.00K | 1.95M | 8.34M | 16.76M | 1.97M | 44.17K | 8.25M | 384.26K | 437.74K | 477.82K | 794.50K | 645.03K | 1.79M | 1.13M | 835.44K |
| Interest Expense | 6.43M | 3.79M | 5.34M | 12.05M | 2.61M | 46.00K | 4.00K | 6.31K | 22.96K | 195.78K | 407.36K | 2.32M | 632.49K | 203.48K | 8.60K | 13.92K | 29.16K |
| Depreciation & Amortization | 18.52M | 18.44M | 14.16M | 9.82M | 6.88M | 2.38M | 3.37M | 2.21M | 1.91M | 1.67M | 45.93M | 2.42M | 804.87K | 1.58M | 368.22K | 400.92K | 852.93K |
| EBITDA | -92.64M | -76.38M | -86.46M | -34.68M | -105.09M | -93.79M | -108.08M | -65.32M | -26.21M | 370.08K | 1.17M | -26.14M | -25.31M | -12.98M | -12.25M | -3.36M | -5.99M |
| EBITDA Ratio | -12,269.67% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -52.00% | -16.86% | 5.13% | -93.98% | -118.21% | -61.87% | -59.13% | -21.56% | -148.45% |
| Operating Income | -106.63M | -89.67M | -85.44M | -85.44M | -123.55M | -105.09M | -92.65M | -63.96M | -30.53M | -6.38M | -80.62M | -26.14M | -25.31M | -15.25M | -13.50M | -4.80M | -7.78M |
| Operating Income Ratio | -14,122.65% | -467.72% | -115.54% | -115.54% | -813.38% | -825.47% | -367.83% | -150.20% | -55.46% | -24.25% | -353.35% | -93.98% | -122.09% | -72.68% | -77.92% | -32.48% | -189.73% |
| Total Other Income/Expenses | -16.42M | -8.94M | 6.73M | -12.05M | 8.34M | 16.76M | -11.03M | 47.00K | 8.38M | 8.63M | -3.99M | -1.90M | 172.38K | 486.77K | 812.28K | 1.10M | 810.65K |
| Income Before Tax | -123.05M | -98.60M | -97.48M | -97.48M | -115.21M | -88.33M | -103.68M | -63.92M | -22.27M | 2.25M | -81.09M | -27.87M | -25.14M | -14.76M | -11.72M | -3.68M | -6.97M |
| Income Before Tax Ratio | -16,297.48% | -514.32% | -131.82% | -131.82% | -758.47% | -693.84% | -411.63% | -150.09% | -40.47% | 8.56% | -355.39% | -100.21% | -121.26% | -70.36% | -67.66% | -24.94% | -169.96% |
| Income Tax Expense | -6.21M | 87.00K | -11.20M | -24.91M | -24.53M | 16.81M | -13.20M | -1.54M | -926.03K | 2.42M | 4.68M | 1.58M | 5.76M | -4.04M | -6.20M | -3.87M | -2.61M |
| Net Income | -101.06M | -98.69M | -86.28M | -72.57M | -90.69M | -78.69M | -99.37M | -63.92M | -22.46M | 24.32K | -84.28M | -29.45M | -30.90M | -10.72M | -5.52M | 185.15K | -4.36M |
| Net Income Ratio | -13,385.30% | -514.78% | -116.68% | -98.14% | -597.01% | -618.12% | -394.51% | -150.10% | -40.81% | 0.09% | -369.38% | -105.89% | -149.05% | -51.11% | -31.87% | 1.25% | -106.22% |
| EPS | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.81 | -0.66 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| EPS Diluted | -1.77 | -2.17 | -1.93 | -1.71 | -2.14 | -1.93 | -2.78 | -1.78 | -0.65 | 0.00 | -4.08 | -1.48 | -2.19 | -0.76 | -0.39 | 0.01 | -0.31 |
| Weighted Avg Shares Out | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.29M | 34.15M | 26.07M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
| Weighted Avg Shares Out (Dil) | 57.01M | 45.55M | 44.82M | 42.50M | 42.44M | 40.77M | 35.69M | 35.81M | 34.52M | 26.19M | 20.65M | 19.94M | 14.13M | 14.13M | 14.13M | 14.13M | 14.13M |
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial...
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders...
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for...
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for...
There's a Lot of Upside For Emerging Gene-Editing Companies
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing...
CLLS Stock: 23.01% Drop Explaination
The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why.
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review...
Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Mark Frattini - Chief Medical Officer Bing Wang - Chief Financial...
Cellectis to Report Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for...
Source: https://incomestatements.info
Category: Stock Reports